

Akadeum's buoyant microbubble technology	
offers a simple yet powerful shift in cell separation, negative selection that can be	i -
incorporated directly into existing workflows. This	
approach offers the flexibility for the user to	
development to manufacturing without sacrificing	
cell health or performance.	
o Small scale manual processing	1.00
 Manual in-bag closed system 	1 - C
O In-bag with existing instrumentation	Sı
O Alerion [™] Microbubble Cell Separation System + BioBise [™] Consumptie	U
System DiolAise Consumable	
ANY SYSTEM WITH ANY STARTING MATERIAL	
With microbubbles, the flexibility isn't limited to	I CD
how you process but extends to what you process	CD
too. Akadeum's kits are robust, enabling the	Aka
• Fresh unprocessed apheresis	apr An
• Platelet depleted apheresis	prc
o Cryopreserved apheresis	iso
o PBMCs	ISO
o Cryopreserved PBMCs	res
NEGATIVE SELECTION AT SCALE	
selection workflows with Akadeum's Human T Cell	
Leukopak Isolation Kit (TCI) from process	ge
development to clinical manufacturing. The below	enta
brocessing 500 million cells in a 50 mL conical	erce
tube or 15 billion cells in a BioRise [™] consumable.	D3 P
TCI Scalability	Ū
100 50mL tube	
	1.00
	1000
	100
	80
cp vield cp billth	60
	4.01



674 S. Wagner Rd

Ann Arbor, MI 48103

www.akadeum.con

Healthier Cells with Akadeum's Microbubbles: A Novel Approach to **Gentle and Efficient Cell Isolation**

C.B. Christensen, J. Chen, B.M. Macintyre, J. RoseFigura, J.R. Roussey, and W. R. Lloyd Akadeum Life Sciences[®], Ann Arbor, MI



plation. Average postere 91.8% and 99.8%, spectively.



Figure 3. Consistently high CD3+ cell purity

Purity

Apheresis material from 55 donors was processed using Thermo Fisher's Rotea system for platelet depletion, followed by T cell isolation with Akadeum's TCI kit. Average CD3+ cell purity was 94%, demonstrating the reliability and efficiency of integrating microbubbles into existing workflows.



ALERION™ MICROBUBBLE CELL SEPARATION SYSTEM

Figure 5. Consistent performance by first-time Alerion[™] users Apheresis material from 10 donors was processed by first-time users of Akadeum's microbubble technology and Alerion[™] platform. Platelet depletion was performed using either Fresenius Kabi's LOVO system, Thermo Fisher's Rotea[™], or a standard centrifugation protocol. CD3+ T cells were subsequently isolated using Akadeum's TCI kit. Average CD3+ cell purity was 91% and the average yield was 73.2%. These results demonstrate the robust and consistent performance of microbubble-based separation technology, even in workflows conducted by users with no prior experience.

Copyright © 2025, Akadeum Life Sciences®. All rights reserved including but not limited to text, graphics, figures, and images. Akadeum Life Sciences'® name and logo are trademarks of Akadeum Life Sciences®, Inc. Akadeum products are for in vitro research use only and are not intended for human or animal in vivo, therapeutic, or diagnostic use. Patent No. 11,291,931 Patent Pending No. 18/114,130



- Consistent high performance
- Significantly reduce time

COMPATIBILITY EXAMPLES:

- Thermo Fisher's Rotea™
- O Cytiva's Sepax[™]
- o Lonza's Cocoon[™]
- Terumo's Optia[™] & Quantum[™]
- Fresenius Kabi's LOVO[™]
- MaxCyte's Electroporation System
- Wilson Wolf G-Rex[®]

GMP

Akadeum GMP products are manufactured according to cGMP at Akadeum Life Sciences, Ann Arbor, MI, under a quality management system in compliance with 21 CFR 820, 211, 210 and 11. They are developed following USP <1043> and ISO 20399 recommendations on ancillary materials.